Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eksp Klin Gastroenterol ; (9): 9-14, 2010.
Artigo em Russo | MEDLINE | ID: mdl-21427917

RESUMO

In the article are shown the results of the study being the first of the detailed population-based study of the prevalence of gastroesophageal reflux disease in Russia based on the reflux questionnaire Mayo Clinic. The high prevalence of gastroesophageal reflux disease was determined among the inhabitants of Saransk. We made the comparative analysis of the symptoms of the disease with regard for sex and age of the respondents.


Assuntos
Refluxo Gastroesofágico/epidemiologia , Vigilância da População , Adolescente , Adulto , Fatores Etários , Idoso , Diagnóstico Diferencial , Feminino , Refluxo Gastroesofágico/diagnóstico , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Federação Russa/epidemiologia , Fatores Sexuais , Inquéritos e Questionários , População Urbana/estatística & dados numéricos , Adulto Jovem
2.
Artigo em Russo | MEDLINE | ID: mdl-18595465

RESUMO

Forty-eight patients with duodenal peptic ulcer disease infected with Helicobacter pylori were examined. All patients undergo conventional 1-week eradication therapy. After its ending the patients were randomized to two groups: those who will be treated by synbiotics or control group. Normoflorin B and Normoflorin L, which contain bifidobacteria or lactobacilli in complex with different microelements, vitamins, aminoacids, organic acids, and antioxidants, were used as synbiotics. Morphologic study of biopsy samples of small intestine mucosa were performed in patients from both groups. It was determined that eradication therapy worsened existing symptoms of dyspepsia in 80.9% of cases or lead to their emergence, connected with dysbiotic manifestations, in 55.5% of patients. Inclusion of synbiotics in complex therapy resulted in rapid and effective elimination of dyspeptic symptoms, promoted recovery of affected morphologic and functional states of small intestine mucosal epithelium, and optimized metabolic processes important for the digestion.


Assuntos
Anti-Infecciosos/efeitos adversos , Antiulcerosos/efeitos adversos , Úlcera Duodenal/complicações , Infecções por Helicobacter/complicações , Helicobacter pylori , Enteropatias , Probióticos/uso terapêutico , Adulto , Idoso , Anti-Infecciosos/uso terapêutico , Antiulcerosos/uso terapêutico , Bifidobacterium , Biópsia , Quimioterapia Combinada , Úlcera Duodenal/tratamento farmacológico , Dispepsia/patologia , Dispepsia/terapia , Feminino , Infecções por Helicobacter/tratamento farmacológico , Humanos , Enteropatias/induzido quimicamente , Enteropatias/fisiopatologia , Enteropatias/terapia , Mucosa Intestinal/patologia , Intestino Delgado/patologia , Lactobacillus acidophilus , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...